{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:51Z","timestamp":1787009031159,"version":"build-2736575974"},"reference-count":66,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"United States National Institute of Allergy and Infectious Diseases","award":["R01AI119037"],"award-info":[{"award-number":["R01AI119037"]}]},{"name":"Wellcome Trust Sir Henry Dale Fellowship","award":["220587\/Z\/20\/Z"],"award-info":[{"award-number":["220587\/Z\/20\/Z"]}]},{"name":"Adult Clinical Trial Group"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068634"],"award-info":[{"award-number":["UM1 AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI068636"],"award-info":[{"award-number":["UM1 AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 AI106701"],"award-info":[{"award-number":["UM1 AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In South Africa, an estimated 11% of the population have high alcohol use, a major risk factor for TB. Alcohol and other substance use are also associated with poor treatment response, with a potential mechanism being altered TB drug pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs in participants with pulmonary TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We prospectively enrolled participants \u226515 years old, without HIV, and initiating drug-susceptible TB treatment in Worcester, South Africa. Alcohol use was measured via self-report and blood biomarkers. Other illicit substances were captured through a urine drug test. Plasma samples were drawn 1 month into treatment pre-dose, and 1.5, 3, 5 and 8 h post-dose. Non-linear mixed-effects modelling was used to describe the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol. Alcohol and drug use were tested as covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 104 participants, of whom 70% were male, with a median age of 37 years (IQR 27\u201348). Alcohol use was high, with 42% and 28% of participants having moderate and high alcohol use, respectively. Rifampicin and isoniazid had slightly lower pharmacokinetics compared with previous reports, whereas pyrazinamide and ethambutol were consistent. No significant alcohol use effect was detected, other than 13% higher ethambutol clearance in participants with high alcohol use. Methaqualone use reduced rifampicin bioavailability by 19%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No clinically relevant effect of alcohol use was observed on the pharmacokinetics of first-line TB drugs, suggesting that poor treatment outcome is unlikely due to pharmacokinetic alterations. That methaqualone reduced rifampicin means dose adjustment may be beneficial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkae206","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T13:37:22Z","timestamp":1718026642000},"page":"2022-2030","source":"Crossref","is-referenced-by-count":8,"title":["The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-8210","authenticated-orcid":false,"given":"Marie","family":"Wijk","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9002-8087","authenticated-orcid":false,"given":"Kamunkhwala","family":"Gausi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Malatesta","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E","family":"Weber","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston University School of Medicine and Boston Medical Centre , Boston, MA , USA"},{"name":"Department of Epidemiology, Boston University School of Public Health , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Court","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn","family":"Myers","sequence":"additional","affiliation":[{"name":"Curtin enAble Institute, Curtin University , WA , Australia"},{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town , South Africa"},{"name":"Department of Psychiatry and Mental Health, University of Cape Town , Rondebosch , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Carney","sequence":"additional","affiliation":[{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town , South Africa"},{"name":"Department of Psychiatry and Mental Health, University of Cape Town , Rondebosch , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles D H","family":"Parry","sequence":"additional","affiliation":[{"name":"Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council , Cape Town , South Africa"},{"name":"Department of Psychiatry, Stellenbosch University , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-7895","authenticated-orcid":false,"given":"C Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Boston University School of Public Health , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura F","family":"White","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9070-8699","authenticated-orcid":false,"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M","family":"Warren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2358-0135","authenticated-orcid":false,"given":"Caitlin","family":"Uren","sequence":"additional","affiliation":[{"name":"DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town , South Africa"},{"name":"Centre for Bioinformatics and Computational Biology, Stellenbosch University , Stellenbosch , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6226","authenticated-orcid":false,"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-4559","authenticated-orcid":false,"given":"Frank","family":"Kloprogge","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-079X","authenticated-orcid":false,"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen R","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Boston University School of Medicine and Boston Medical Centre , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"2024073123504570100_dkae206-B1","author":"World Health Organization"},{"key":"2024073123504570100_dkae206-B2","doi-asserted-by":"crossref","first-page":"1700216","DOI":"10.1183\/13993003.00216-2017","article-title":"Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease","volume":"50","author":"Imtiaz","year":"2017","journal-title":"Eur Respir J"},{"key":"2024073123504570100_dkae206-B3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12879-018-3396-y","article-title":"Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol","volume":"18","author":"Myers","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2024073123504570100_dkae206-B4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5588\/ijtld.14.0516","article-title":"Tuberculosis and excess alcohol use in the United States, 1997\u20132012","volume":"19","author":"Volkmann","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024073123504570100_dkae206-B5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"key":"2024073123504570100_dkae206-B6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1128\/AAC.03931-14","article-title":"Impact of nonlinear interactions of pharmacokinetics and mics on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis","volume":"59","author":"Chigutsa","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B7","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024073123504570100_dkae206-B8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1378\/chest.113.5.1178","article-title":"Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients","volume":"113","author":"Kimerling","year":"1998","journal-title":"Chest"},{"key":"2024073123504570100_dkae206-B9","doi-asserted-by":"crossref","first-page":": 2000955","DOI":"10.1183\/13993003.00955-2020","article-title":"Increased bactericidal activity but dose-limiting intolerability at 50 mg\u00b7kg\u22121 rifampicin","volume":"58","author":"Te Brake","year":"2021","journal-title":"Eur Respir J"},{"key":"2024073123504570100_dkae206-B10","first-page":"43","article-title":"Pharmacokinetics of isoniazid in patients with pulmonary tuberculosis and alcoholism","volume":"12","author":"Koriakin","year":"1986","journal-title":"Probl Tuberk"},{"key":"2024073123504570100_dkae206-B11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.15288\/qjsa.1964.25.541","article-title":"The acetylation of isoniazid in alcoholics","volume":"25","author":"Lester","year":"1964","journal-title":"Q J Stud Alcohol"},{"key":"2024073123504570100_dkae206-B12","first-page":"1373","article-title":"Unchanged acetylation of isoniazid by alcohol intake","volume":"8","author":"Wilcke","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024073123504570100_dkae206-B13","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.drugalcdep.2011.04.013","article-title":"Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients","volume":"118","author":"McCance-Katz","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"2024073123504570100_dkae206-B14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024073123504570100_dkae206-B15","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1128\/AAC.50.4.1170-1177.2006","article-title":"Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients","volume":"50","author":"McIlleron","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B16","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1128\/AAC.02307-13","article-title":"Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV","volume":"58","author":"Jeremiah","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"2024073123504570100_dkae206-B18","doi-asserted-by":"crossref","first-page":"e0262440","DOI":"10.1371\/journal.pone.0262440","article-title":"Transmission of tuberculosis among illicit drug use linkages (TOTAL): a cross-sectional observational study protocol using respondent driven sampling","volume":"17","author":"Carney","year":"2022","journal-title":"PLoS One"},{"key":"2024073123504570100_dkae206-B19","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.3109\/10826084.2010.481594","article-title":"Illicit drug use and treatment in South Africa: a review","volume":"45","author":"Peltzer","year":"2010","journal-title":"Subst Use Misuse"},{"key":"2024073123504570100_dkae206-B20","doi-asserted-by":"crossref","first-page":"e00490-17","DOI":"10.1128\/AAC.00490-17","article-title":"Pharmacokinetics of pyrazinamide and optimal dosing regimens for drug-sensitive and -resistant tuberculosis","volume":"61","author":"Chirehwa","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B21","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5588\/ijtld.17.0697","article-title":"Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications","volume":"22","author":"Court","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024073123504570100_dkae206-B22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/AAC.01830-15","article-title":"Model-based evaluation of higher doses of rifampin using a semimechanistic model incorporating autoinduction and saturation of hepatic extraction","volume":"60","author":"Chirehwa","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B23","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"2024073123504570100_dkae206-B24","volume-title":"The Art of Modeling","author":"Bonate","year":"2006"},{"key":"2024073123504570100_dkae206-B25","article-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment","author":"World Health Organization","year":"2020"},{"key":"2024073123504570100_dkae206-B26","author":"Babor"},{"key":"2024073123504570100_dkae206-B27","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Litten","year":"2012"},{"key":"2024073123504570100_dkae206-B28","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/dta.3340","article-title":"Consensus for the use of the alcohol biomarker phosphatidylethanol (PEth) for the assessment of abstinence and alcohol consumption in clinical and forensic practice (2022 Consensus of Basel)","volume":"14","author":"Luginb\u00fchl","year":"2022","journal-title":"Drug Test Anal"},{"key":"2024073123504570100_dkae206-B29","article-title":"What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS","author":"World Health Organization","year":"1999"},{"key":"2024073123504570100_dkae206-B30","first-page":"59","article-title":"H3Africa: current perspectives","volume":"11","author":"Mulder","year":"2018","journal-title":"Pharmgenomics Pers Med"},{"key":"2024073123504570100_dkae206-B31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/pgs.11.122","article-title":"Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes","volume":"13","author":"Hein","year":"2012","journal-title":"Pharmacogenomics"},{"key":"2024073123504570100_dkae206-B32","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/alcalc\/agu037","article-title":"Comparison of phosphatidylethanol results to self-reported alcohol consumption among young injection drug users","volume":"49","author":"Jain","year":"2014","journal-title":"Alcohol Alcohol"},{"key":"2024073123504570100_dkae206-B33","volume-title":"NONMEM User\u2019s Guide, Part V. Introductory Guide","author":"Boeckmann","year":"2011"},{"key":"2024073123504570100_dkae206-B34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2014a perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"2024073123504570100_dkae206-B35","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2024073123504570100_dkae206-B36","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-75936-4","volume-title":"Software for Data Analysis: Programming with R","author":"Chambers","year":"2008"},{"key":"2024073123504570100_dkae206-B37","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"2024073123504570100_dkae206-B38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/cid\/ciac001","article-title":"Influence of NAT2 genotype and maturation on isoniazid exposure in low-birth-weight and preterm infants with or without human immunodeficiency virus (HIV) exposure","volume":"75","author":"B\u00e9ranger","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024073123504570100_dkae206-B39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.2011.03940.x","article-title":"Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients","volume":"72","author":"Wilkins","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"2024073123504570100_dkae206-B40","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkac188","article-title":"Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis","volume":"77","author":"Gausi","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2024073123504570100_dkae206-B41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2024073123504570100_dkae206-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"2024073123504570100_dkae206-B43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2024073123504570100_dkae206-B44","author":"NCBI"},{"key":"2024073123504570100_dkae206-B45","author":"NCBI"},{"key":"2024073123504570100_dkae206-B46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2024073123504570100_dkae206-B47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2024073123504570100_dkae206-B48","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1093\/jac\/dkab336","article-title":"Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial","volume":"76","author":"Garcia-Prats","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024073123504570100_dkae206-B49","doi-asserted-by":"crossref","first-page":"e0043123","DOI":"10.1128\/aac.00431-23","article-title":"Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin","volume":"67","author":"Kengo","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B50","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2165\/00003088-198409060-00003","article-title":"Clinical pharmacokinetics of the antituberculosis drugs","volume":"9","author":"Holdiness","year":"1984","journal-title":"Clin Pharmacokinet"},{"key":"2024073123504570100_dkae206-B51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cpt.2044","article-title":"Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping","volume":"109","author":"Gausi","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2024073123504570100_dkae206-B52","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJMoa1813060","article-title":"Isoniazid preventive therapy in HIV-infected pregnant and postpartum women","volume":"381","author":"Gupta","year":"2019","journal-title":"N Engl J Med"},{"key":"2024073123504570100_dkae206-B53","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1164\/rccm.202103-0534OC","article-title":"A semimechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis: results from a randomized clinical trial","volume":"204","author":"Gausi","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024073123504570100_dkae206-B54","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/acer.14611","article-title":"Factors associated with phosphatidylethanol (PEth) sensitivity for detecting unhealthy alcohol use: an individual patient data meta-analysis","volume":"45","author":"Hahn","year":"2021","journal-title":"Alcohol Clin Exp Res"},{"key":"2024073123504570100_dkae206-B55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.5588\/ijtld.22.0650","article-title":"Smoked drug use in patients with TB is associated with higher bacterial burden","volume":"27","author":"Myers","year":"2023","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024073123504570100_dkae206-B56","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13690-018-0287-z","article-title":"Impact of alcohol disorder and the use of illicit drugs on tuberculosis treatment outcomes: a retrospective cohort study","volume":"76","author":"Pelissari","year":"2018","journal-title":"Arch Public Health"},{"key":"2024073123504570100_dkae206-B57","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12889-019-7127-0","article-title":"Cannabis use and the risk of tuberculosis: a systematic review","volume":"19","author":"French","year":"2019","journal-title":"BMC Public Health"},{"key":"2024073123504570100_dkae206-B58","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1017\/S0950268817002631","article-title":"Drug addiction and alcoholism as predictors for tuberculosis treatment default in Brazil: a prospective cohort study","volume":"145","author":"Silva","year":"2017","journal-title":"Epidemiol Infect"},{"key":"2024073123504570100_dkae206-B59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0006-2952(69)90222-6","article-title":"Biochemical changes in rat liver in response to treatment with drugs and other agents\u2014III: effects of centrally acting drugs","volume":"18","author":"Platt","year":"1969","journal-title":"Biochem Pharmacol"},{"key":"2024073123504570100_dkae206-B60","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2217\/pgs-2018-0166","article-title":"Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis","volume":"20","author":"Naidoo","year":"2019","journal-title":"Pharmacogenomics"},{"key":"2024073123504570100_dkae206-B61","doi-asserted-by":"crossref","first-page":"e01978-19","DOI":"10.1128\/AAC.01978-19","article-title":"Population pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in pregnant South African women with tuberculosis and HIV","volume":"64","author":"Abdelwahab","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B62","doi-asserted-by":"crossref","first-page":"e0141002","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PLoS One"},{"key":"2024073123504570100_dkae206-B63","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1128\/AAC.00274-11","article-title":"Population pharmacokinetics of ethambutol in South African tuberculosis patients","volume":"55","author":"J\u00f6nsson","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14787210.2019.1555031","article-title":"Current research toward optimizing dosing of first-line antituberculosis treatment","volume":"17","author":"McIlleron","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024073123504570100_dkae206-B65","doi-asserted-by":"crossref","first-page":"e0142622","DOI":"10.1128\/aac.01426-22","article-title":"Optimizing moxifloxacin dose in MDR-TB participants with or without efavirenz coadministration using population pharmacokinetic modeling","volume":"67","author":"Chirehwa","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123504570100_dkae206-B66","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.3390\/antibiotics10121559","article-title":"Is dosing of ethambutol as part of a fixed-dose combination product optimal for mechanically ventilated ICU patients with tuberculosis? A population pharmacokinetic study","volume":"10","author":"Beraldi-Magalhaes","year":"2021","journal-title":"Antibiotics (Basel)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/2022\/58688872\/dkae206.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/2022\/58688872\/dkae206.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:51:45Z","timestamp":1722477105000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/2022\/7710581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":66,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,10]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae206","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,10]]}}}